Document is current
Any future updates will be listed below
-
Authors
Fefeu, Mylène
Blatzer, Michael
Kneppers, Anita https://orcid.org/0000-0003-4901-5468
Briand, David https://orcid.org/0000-0001-5680-8242
Rocheteau, Pierre
Haroche, Alexandre
Hardy, David https://orcid.org/0000-0001-5874-4377
Juchet-Martin, Mélanie
Danckaert, Anne https://orcid.org/0000-0001-8984-643X
Coudoré, François
Tutakhail, Abdulkarim https://orcid.org/0000-0002-4855-8084
Huchet, Corinne
Lafoux, Aude
Mounier, Rémi
Mir, Olivier
Gaillard, Raphaël
Chrétien, Fabrice https://orcid.org/0000-0002-2794-1383
- License Information
-
More Information
Article History
Received: 16 June 2021
Accepted: 3 July 2024
First Online: 31 July 2024
Competing interests
: R.G. has received compensation as a member of the scientific advisory board of Janssen, Lundbeck, Novartis, Roche, SOBI, Takeda. He has served as a consultant and/or a speaker for Astra Zeneca, Boehringer-Ingelheim, Pierre Fabre, Eli Lilly, Lundbeck, LVMH, MAPREG, Novartis, Otsuka, Pileje, SANOFI, Servier and received compensation, and he has received research support from Servier. He is a board member of the Regstem company. O.M. has received consultancy fees from Astra-Zeneca, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Ipsen, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma. O.M. is an employee and shareholder of Amgen since Feb 1st, 2022. FCh is a board member of the Regstem company. The remaining authors have nothing to disclose.
